

Bod commences import of cannabis products

- **Bod commences import of Linnea's proprietary CBD powder into Australia– delivery expected mid-February 2018**
- **Significant milestone towards commencement of Phase I Clinical Trials**
- **Delivery of CBD powder to be integrated into 'trial ready' sublingual wafer – development progressing well at iX Biopharma's Australian facility**
- **Formulation to take 6-8 weeks with Phase I Clinical Trials beginning shortly thereafter**
- **Importation of Linnea's proprietary CBD oil to follow – discussions with Australian Government progressing well**

Sydney, Australia – 5 February 2018: Developer and distributor of natural, evidence-based cosmetics and natural medicines, Bod Australia Limited ("Bod" or the "Company") (ASX: BDA) is pleased to advise that it has commenced importation of cannabis into Australia under the Permission to Import permit granted by the Office of Drug Control.

Under the permit, Bod is authorised to import Linnea Natural Pharma Solutions' (Linnea) proprietary 15% cannabidiol (CBD) powder, which will be used in upcoming Phase I Clinical Trial. Now that necessary approvals have been granted, Bod will finalise a product order with Linnea and with delivery expected by mid-February.

Once received, the product will be incorporated into the Company's sublingual wafer, which is currently being developed through Bod's exclusive partner iX Biopharma, at iX Biopharma's wholly owned Australian facility. This process is expected to take approximately six to eight weeks and will provide the Company with a unique CBD delivery method to be tested in Phase I Clinical Trials.

Further to this significant development, the Company also advises that it is in ongoing discussions with the Department of Health to import Linnea's proprietary CBD oil products. Pending this approval, Bod will begin to generate revenues as it is made available to patients through Special Access Scheme Category B. Board and management look forward to updating the market as these discussions progress.

Bod Australia CEO Jo Patterson said: "This is a significant milestone for the Company and another important step in the commencement of our Phase I Clinical Trials to test the safety, tolerability and pharmacokinetics of Linnea's unique cannabis extracts for use in natural medicines and cosmetic products.

"We are currently finalising our order with Linnea and look forward to receiving the powder in the coming weeks. We will then work closely with iX Biopharma to finalise the delivery method and commence Phase I Trials as soon as possible.

"We are also pleased to advise that our ongoing discussions with the Office of Drug control regarding additional product imports are progressing well, with the view to importing Linnea's market-leading CBD oils. If successful, this will mark another important milestone for the Company as we begin to generate sales of cannabis products, adding to our growing revenue profile.

"We look forward to updating the market as our 'trial ready' product is finalised and Phase I Clinical Trials commence, as well as the other developments the Company has in the pipeline regarding enhancements to the product portfolio, an increase in distribution channels and progression of international opportunities."

For more information: bodaustralia.com

- ENDS -

For personal use only

About Bod Australia

Bod Australia Limited operates two integrated business units. The Company is a developer and distributor of cosmetics and natural medicines, focused on all natural, evidence based products. Bod has developed a significant distribution footprint in the Australian market with access to over 800 pharmacies and is also targeting Asian markets through key daigou relationships. Bod Australia is also building a sustainable, multi-faceted cannabis business through a supply and collaboration agreement with Swiss botanical extracts manufacturer, Linnea Natural Pharma Solutions. The Company aims to develop a range of over the counter and therapeutic products based on GMP-certified cannabis extracts.

For more information please contact:

Jo Patterson
Bod Australia
+61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

For personal use only